ArticleMolecular oncology2025
KRAS
Abstract read
In one paragraph
Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Organoids in translation: a bench-to-bedside framework for pancreatic cancer precision medicine.Journal of translational medicine · 2026Pooled it
- Targeting MAPK Pathways in Skin, Thyroid, and Pancreatic Cancer: A Perspective on Synthetic Inhibitors and Natural Modulators.Advanced biology · 2026Review
- Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.Cancer research communications · 2026Article
- Targeting metabolic dependencies to reverse chemoradiotherapy resistance in colorectal cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- SHP2 as a pivotal modulator of the tumor microenvironment in gastrointestinal cancers: from mechanisms to targeted therapies.Journal of translational medicine · 2026Review
- The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma.MedComm · 2026Article
- Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells.Cell death & disease · 2025Article
- Pan-ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer.United European gastroenterology journal · 2025Article
- Pancreatic cancer in the era of precision medicine: challenges, advances, and the future of therapeutic strategies.Journal of the Egyptian National Cancer Institute · 2025Review
- Integrated real-time imaging of executioner caspase dynamics, apoptosis-induced proliferation, and immunogenic cell death using a stable fluorescent reporter platform.Cell death discovery · 2025Article
- KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma.Translational oncology · 2025Article
- PRMT5 inhibitors: Therapeutic potential in pancreatic cancer.Translational oncology · 2025Review
- Review
- Cancer 3D Models: Essential Tools for Understanding and Overcoming Drug Resistance.Oncology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Constanza Tapia ContrerasDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Jonas Dominik FalkeDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Dana-Magdalena SeifertDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Carolin SchneiderDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Lukas KraußDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Xin FangDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Denise MüllerInstitute of Pathology, University Medical Center, Göttingen, Germany.ORCID 0000-0001-6231-7431
Engin DemirdizenDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Melanie SpitznerDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Tiago De OliveiraDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Christian SchneeweisInstitute for Translational Cancer Research and Experimental Cancer Therapy, Technical University Munich, Germany.
Jochen GaedckeDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Silke KaulfußClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Germany.
Kimia MirzakhaniClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Germany.
Bernd WollnikClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Germany.
Karly ConradsClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Germany.ORCID 0009-0006-4536-8564
Tim BeißbarthClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Germany.
Gabriela SalinasClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Germany.
Jonas HügelClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Germany.
Nils BeyerClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Germany.
Sophia RheinländerClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Germany.
Ulrich SaxClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Germany.
Matthias WirthDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Lena-Christin ConradiDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Maximilian ReichertMedical Clinic and Polyclinic II, Klinikum rechts der Isar, Technical University Munich, Germany.
Volker EllenriederClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Germany.
Philipp StröbelInstitute of Pathology, University Medical Center, Göttingen, Germany.
Michael GhadimiDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Marian GradeDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.
Dieter SaurInstitute for Translational Cancer Research and Experimental Cancer Therapy, Technical University Munich, Germany.
Elisabeth HessmannClinical Research Unit 5002, KFO5002, University Medical Center Göttingen, Germany.
Günter SchneiderDepartment of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Germany.ORCID 0000-0003-1840-4508
Funding
Bavarian Ministry of Economic Affairs, Regional Development and Energy project EISglobe LSM-2104-0017BMBF FAIRPACT 01KD2208BBMBF QuE-MRT 13N16450BMBF SATURN3 01KD2206PDeutsche Forschungsgemeinschaft KFO5002Deutsche Forschungsgemeinschaft RE 3723/4-1Deutsche Forschungsgemeinschaft SCHN 959/3-2Deutsche Forschungsgemeinschaft SCHN 959/6-1Deutsche Forschungsgemeinschaft SCHN959/7-1Deutsche Forschungsgemeinschaft SCHN959/8-1Deutsche Forschungsgemeinschaft WI 6148/1-1Deutsche Krebshilfe 70112505Deutsche Krebshilfe 70113760Deutsche Krebshilfe 70115444DKTK (German Cancer Consortium) Strategic Initiative Organoid PlatformHector-Stiftung M2408Volkswagenstiftung ZN3424Wilhelm Sander-Stiftung 2021.139.1Wilhelm Sander-Stiftung 2022.074.1Wilhelm Sander-Stiftung 2023.027.1
Abstract
Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options, emphasizing the urgent need for effective therapies. The predominant driver in PDAC is mutated KRAS proto-oncogene, KRA, present in 90% of patients. The emergence of direct KRAS inhibitors presents a promising avenue for treatment, particularly those targeting the KRAS
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorDrug Screening Assays, AntitumorHumansMutationProtein Kinase InhibitorsProto-Oncogene MasKRAS protein, humanMAS1 protein, humanProtein Kinase InhibitorsProto-Oncogene MasProto-Oncogene Proteins p21(ras)KRASG12Cpancreatic cancerSHP2SOS1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.